Equip yourself: Knowledge and skills to help get the support you need

Access Barriers Emerge

The landscape of Alzheimer's treatment in Canada shifted dramatically in October 2025 with Health Canada's conditional approval of lecanemab, marketed as Leqembi. This monoclonal antibody, developed by Eisai and Biogen, removes amyloid plaques from the brain, slowing cognitive decline by about 30% in early-stage patients according to clinical trials. Unlike prior symptom-managing drugs, it addresses the disease's underlying pathology, marking a pivotal advance after decades of limited progress. Yet, this breakthrough arrives amid an aging population where dementia cases are surging—over 600,000 Canadians currently affected, expected to reach 1.3 million by 2050.

Public enthusiasm was tempered in February 2026 when Canada's Drug Agency issued a draft recommendation against covering lecanemab under public drug plans, citing uncertainties in long-term clinical benefits relative to its high cost. Estimates suggest the drug could exceed $30,000 annually per patient, based on U.S. pricing of $26,500, with additional expenses for infusions, monitoring MRIs, and diagnostics. Without reimbursement, access hinges on private insurance or out-of-pocket payments, potentially excluding lower-income families. Advocacy groups, including the Alzheimer Society of Canada, argue this creates inequity, while the agency projects public costs could balloon to $728 million by year three if covered.

In British Columbia, these developments compound existing strains on dementia support. The province's Seniors Advocate reported in 2025 that long-term care waitlists doubled from 2019 levels, with shortfalls forecast to multiply sevenfold by 2035. This leaves caregivers—often family members—managing complex needs without adequate respite, leading to 80% reporting anxiety and exhaustion. Rural areas face amplified challenges, with fewer services prompting earlier hospital admissions or moves to urban facilities, disrupting lives and inflating costs. Nationally, dementia's economic burden includes $15 billion in direct healthcare expenses and $25 billion in lost productivity from caregiving, underscoring the ripple effects on workforce and economy.

Tensions arise between stakeholders: pharmaceutical firms push for broader access, citing real-world data from 2025's Alzheimer’s Association International Conference showing patient satisfaction and safety; health economists warn of unsustainable spending; and ethicists highlight disparities, as ApoE ε4 genetic testing—required for eligibility—raises privacy concerns. Meanwhile, pending reviews of similar drugs like donanemab add uncertainty. Prevention efforts, such as lifestyle interventions potentially delaying onset by years, gain traction but lack systemic integration, leaving gaps in early support navigation.